AstraZeneca and Oxford University acknowledged on Wednesday that a manufacturing error has cast doubt on their recent announcement that their COVID-19 vaccine candidate was up to 90% effective.
The Monday announcement claimed that partial results from larger studies showed AstraZeneca's vaccine had an average 70% effectiveness based on evidence that one dosage amount was roughly 90% effective and another was 62% effective.
In a Wednesday statement, Oxford University said that the manufacturing error had been identified before the late-stage trial was completed and that the team had decided to continue with the study split into two groups after discussing the problem with regulators, according to the Associated Press.
David Salisbury, an associate fellow of the Chatham House's global health program, told the Associated Press that averaging those results is an inaccurate way of presenting the results of the study.
"You've taken two studies for which different doses were used and come up with a composite that doesn't represent either of the doses,″ he said."I think many people are having trouble with that.
Pascal Soriot, the CEO of AstraZeneca, told Bloomberg on Thursday that the company will likely begin another global trial in the wake of those manufacturing errors.
A spokesperson clarified to NBC News that any further studies would "Not [be] a brand new trial" but rather would be an expansion of the variable dosages.
Friday, November 27, 2020
AstraZeneca COVID-19 vaccine study questioned after manufacturing error
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment